Curaleaf Raises Hostile Bid to US$5.00; Aurora Urges Shareholders to Take No Action
ACB sits 74% above its 52-week low of $2.56 on light trading volume (0.3× avg).
Summary
Curaleaf announced a revised hostile bid of US$5.00 per share for Aurora Cannabis, up from US$4.00, and extended the offer deadline to December 4, 2026. Aurora's board has not yet received the formal revised offer and continues to recommend shareholders take no action.
Updates
· SEC SC14D9F/A — Aurora's Special Committee will commence a formal review of Curaleaf's revised US$5.00 bid and shareholders have until at least December 4, 2026 to consider their options.
Key Events · M&A and Partnerships · ACB
-
Revised Hostile Bid Announced
Curaleaf stated its intention to file a Notice of Variation and Change to revise its hostile bid to US$5.00 per Aurora share, consisting of 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash — up from the original US$4.00 per share offer.
-
Bid Expiry Extended to December 4
Curaleaf agreed to extend the expiry of its hostile bid to 11:59pm Mountain Time on December 4, 2026, giving Aurora shareholders additional time to consider the offer.
-
Pro Forma Financials to Be Provided
In response to Aurora's application to the Alberta Securities Commission, Curaleaf agreed to include required pro forma financial statements in its bid circular, addressing a deficiency Aurora had identified.
-
Aurora Maintains 'Take No Action' Stance
Aurora's Special Committee has not yet received the formal revised offer and will conduct a thorough review before issuing a recommendation. Shareholders are advised to take no action until the Board communicates its formal recommendation.
Analysis · ACB · Life Sciences
Curaleaf has signaled a revised hostile bid of US$5.00 per Aurora share — a 25% increase over its original US$4.00 offer — consisting of 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash. Aurora's Special Committee has not yet received the formal Notice of Variation and Change, so no recommendation has been made. The bid expiry has been extended to December 4, 2026, and Curaleaf has agreed to provide pro forma financial statements after Aurora's Alberta Securities Commission application. This is a material escalation in the takeover contest, but the revised terms are not yet formal and Aurora continues to advise shareholders to take no action.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 36.1% of the 1056 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288.9M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.